Weber, Michael

Background Neurofibromatosis type 1 (NF1) is a genetic disorder in which plexiform neurofibromas (PNs) develop in approximately 30% to 50% of affected individuals, often causing substantial morbidity. Treatment of NF1-associated PNs is challenging due to disease variability and tumor complexity. Observations In the Phase 2b ReNeu trial (NCT03962543), mirdametinib, a mitogen-activated protein kinase kinase 1/2 (MEK) inhibitor, demonstrated efficacy and a manageable safety profile in children and adults with symptomatic PNs, achieving confirmed objective responses in 52% of children and 41% of adults, with substantial reductions in target tumor PN volume and improvements in patient- and parent proxy-reported outcomes. However, dermatologic adverse events (AEs) are common with MEK inhibitors, including mirdametinib, and can impact adherence and quality of life. While the ReNeu protocol included supportive care considerations for skin reactions associated with mirdametinib, some investigators recognized a need for more detailed guidance. The ReNeu Scientific Steering Committee, in collaboration with oncology and oncodermatology experts, developed expert-driven recommendations for the proactive management of mirdametinib-related skin AEs. Conclusions These strategies emphasize early recognition, individualized care, and timely intervention to help reduce the severity of mirdametinib-related skin AEs, minimize dose modifications, and support treatment continuity and long-term treatment goals. Although these recommendations were specifically developed for mirdametinib based on ReNeu trial experience, they may also provide practical guidance for managing skin AEs associated with other MEK inhibitors in clinical practice.

Introduction: This paper reports on the results of a survey that was sent to every recipient of a standardised Community Paramedic™ (CP) curriculum. The survey was sent out to 223 post-secondary educators and Government officials. Out of 223 total surveys, 68 (30.49%) responses were received. Forty-seven of the 68 responses (69.11%) answered the question: ‘When are you planning on giving a community paramedic course?’; 35 of the 47 respondents (74.46%) indicated that their institution had already conducted a CP course, was currently conducting a CP course, or are planning on conducting a CP course within the next five years; of the additional 12 programmes (25.53%), 6 (13.0%) were waiting for state approval, and the other 6 (13.0%) were unknown as to when they would be offering a course. Conclusions: At the time of the survey, many CP courses were in planning stages by programmes that had received the standardised CP curriculum, both in the US and internationally. It appears that the CP curriculum that has been disseminated internationally has been broadly accepted and will be widely utilised.